Lundbeck maintains guidance after exceeding expectations in Q1
After surpassing the consensus analyst estimate in terms of operating result and revenue, Lundbeck is maintaining its guidance for the full-year 2022.
Lundbeck has released its report for the first three months of 2022, which reveals revenue and EBIT (earnings before interest and taxes) results that exceed the analyst consensus estimates.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck poaches Zealand Pharma VP
For subscribers
